Ubicom Holdings. Inc. · TSE:3937
Ubicom — Q1 FY2025 Earnings Presentation
38 slides from Ubicom's earnings presentation, Aug 7, 2025
Slide 1: FY2025 Q1 Financial Results Materials
Ubicom Holdings, Inc. (Prime Market of TSE: 3937) FY2025 Q1 Financial Results Materials August. 7, 2025
Slide 2: Table of Contents
Table of Contents 01 Overview of Consolidated Financial Results (P/L) for FY2025 Q1 P.3 02 Medical Business P.4 03 Technology Consulting Business P.7 04 Growth Strategies P.12 05 Dividend Policy P.27 06 Business Forecast ＆ Performance Trends P.29 07 Appendix P.31 © Ubicom Holdings, Inc. 2
Slide 3: Overview of Consolidated Financial Results (P/L) for FY2025 Q1
Overview of Consolidated Financial Results (P/L) for FY2025 Q1 Operating income, ordinary income, and net income reached record highs for the first quarter. Although revenue declined due to the continued strategic selection of orders in Technology Consulting business in response to the impact of U.S
Slide 4: Medical Business
Medical Business 4
Slide 5: Medical Business: FY2025 1Q Segment Performance Overview
Medical Business： FY2025 1Q Segment Performance Overview By implementing the following measures, the company achieved record highs in both sales and operating income through the stock expansion of the Mighty series using the AI × subscription model and increased average user unit price. The medical
Slide 6: User Trend of the Core Solution Mighty Series
AI×Subscription Model User’s Trend of the Core Solution「Mighty」Series The implementation of workstyle reforms for medical doctors in April 2024 has led to an acceleration of digital transformation in the medical industry. While focusing on converting existing users, the number of users is steadily i
Slide 7: Technology Consulting Business
Technology Consulting Business 7
Slide 8: Technology Consulting Business: Overview by Segment for 1Q of FY2025
Technology Consulting Business： Overview by Segment for 1Q of FY2025 (Business Performance) Due to the following factors, Technology Consulting business recorded a YoY decline in both sales and operating income. However, progress remained within the expected budget range. 1Q of FY2024 (Accumulated)
Slide 9: Investments to reinforce mid- to long-term profitability
Beginning in FY2025, investments will be initiated the aim of reinforcing its mid-to long-term profitability. External Environment U.S. tariffs have increased price pressure from some Changes in Supply Chain originating from U.S.-China relations clients, mainly in manufacturing China's domestic econ
Slide 10: Factors Behind the Decline in Operating Income
Technology Consulting Business： Overview by Segment for 1Q of FY2025 (Business Performance) Factors Behind the Decline in Operating Income Due to One-Time Costs and Structural Reform (YoY Comparison) (Unit: million yen) Increase 増加 Decrease 減少 Total 合計 180 The impact was 17 limited to Q2. 160 The im
Slide 11: Technology Consulting Business FY2025 Policy
Technology Consulting Business FY2025 Policy With a view to further growth in FY2025 3Q and beyond, measures to strengthen profitability over 8,000 the medium to long term, while anticipating short-term cost increases, will be implemented. 7,000 6,000 01 Continue strategic order selection with a foc
Slide 12: Growth Strategies
Growth Strategies 12
Slide 13: Medical Business: Growth Strategies
Medical Business ～Growth Strategies～ 13
Slide 14: Mid- to Long-Term Growth Strategy
Mid- to Long-Term Growth Strategy ■ Growth Pillars "Stable recurring revenue" × "Non-linear growth through M&A" • Stable growth of stock-type revenue through existing cloud-based solutions (organic growth) • Accelerated growth through expansion of direct sales model via M&As with sales agencies (ino
Slide 15: Impact of M&A Strategy Execution (KPI Changes)
Impact of M&A Strategy Execution (KPI Changes) Over the five years from 2025 to 2030, we will execute 8 to 10 M&A deals with the aim of increasing the group's direct sales ratio. ＜Factors contributing to LTV ※1 improvement＞ Content Measurement details Increase of unit ①Inclusion of agency profits in
Slide 16: Key Strategies for the Short to Medium Term
Key Strategies for the Short to Medium Term Key measures for the current fiscal year in the From this fiscal year onwards, we will medical business accelerate growth investment with a focus • M&A strategy (acquiring distributors nationwide) on M&A strategy. We aim to diversify revenue sources throug
Slide 17: Strengthening the Revenue Structure through M&A of Sales Agencies
Strengthening the Revenue Structure through M&A of Sales Agencies By acquiring sales distributors through M&A, we are shifting from a distributor-based model to a direct sales model within the Group, thereby enhancing our revenue structure. Medical Institution Distributor Medical Institution Groupin
Slide 18: Tactics after the acquisition of ISM Corporation
Short-term strategy：Tactics after the acquisition of ISM Corporation Utilizing ISM's solid customer base. Fukuoka Prefecture's regional medical network, “Tobiumenet” ※includes 835 affiliated medical institutions Conducting new business development through a ‘Group In Commemorative Campaign’ targetin
Slide 19: Long-Term Strategy: M&A Strategy (Nationwide Sales Distributor M&A)
Long-Term Strategy: M&A Strategy (Nationwide Sales Distributor M&A) To maximize profitability in medical business between 2025 and 2030, We will promote a shift to a direct sales model through group-wide M&A initiatives. 95% of Mighty series sales are made via sales agents By positioning the M&A wit
Slide 20: Scenario for Mid-to-Long-Term Growth in the Medical Business
Scenario for Mid-to-Long-Term Growth in the Medical Business To achieve mid-to-long-term growth, we will combine the organic growth of stable stock-type businesses with the Non-linear growth through M&A strategies. Business Growth Strategy Image M&A Target: 8–10 companies by 2025–2030 Creation of ne
Slide 21: Strengthening OEM supply: Mighty QUBE Hybrid in the clinic market
Strengthening OEM supply : Expanded sales of Mighty QUBE® Hybrid in the clinic market Start OEM supply to “medicalforce” cloud-based EMR system for private clinics provided by medicalforce Inc. Promoting sales expansion of Mighty QUBE® Hybrid in the clinic market. This OEM is the second partnership
Slide 22: Technology Consulting Business: Growth Strategies
Technology Consulting Business ～Growth Strategies～ 22
Slide 23: Technology Consulting Business Overview / Strategic Market
Technology Consulting Business Overview / Strategic Market Business Overview ＜Strategic Market for the Technology Consulting Business＞ The Technology Consulting business, backed by over 30 years Healthcare, Finance/Public sector, of trust and experience in offshore development in the Automotive, PC/
Slide 24: Competitive Advantage / Business Environment & Opportunities
Technology Consulting Business: Competitive Advantage / Business Environment & Opportunities 【Competitive Advantages】 Human Resources • Sales: Sales managers from major SIers and global platformer companies • PM: Many PMs are from IBM Japan and major manufacturers • Engineer: ~900 bilingual engineer
Slide 25: Growth Strategy (Short-Term Strategy)
Technology Consulting Business – Growth Strategy (Short-Term Strategy) To strengthen our current profit foundation and improve profitability, we aim to reliably achieve performance forecasts through the expansion of existing businesses and unified group operations. ① Deepening Collaboration with Exi
Slide 26: Growth Strategy (Mid-to-Long-Term Strategy)
Technology Consulting Business – Growth Strategy (Mid-to-Long-Term Strategy) Entering the “Modernization Market” with mid-to-long-term preparations in anticipation of increasing demand for the renewal of social infrastructure systems due to the 2036 problem. Background: Why Legacy System Renewal Has
Slide 27: Dividend Policy
Dividend Policy 27
Slide 28: Dividend Policies to Enable Shareholders to Share in Growth
Dividend Policies to Enable Shareholders to Share in the Benefits from the Growth of Our Company 【Dividend Policies】 ① While concerns over U.S. tariffs had been raised, their actual impact is currently expected to be more limited than initially anticipated. In light of the steady performance of our
Slide 29: Business Forecast & Performance Trends
Business Forecast ＆ Performance Trends 29
Slide 30: Business Forecast and Performance Trends
Business Forecast and Performance Trends Full-scale start of （Unit：million yen） 3,5 00 Operating income 営業利益 the second growth phase 12,400 Operating income from New Businesses, Alliances, and M&A 今後の新規事業・業務提携・M&Aによる営業利益 3,0 00 10,400 Sales 売上高 2,5 00 April, 2022 8,4 00 Moved to TSE Prime Market Dec
Slide 31: Appendix
Appendix 31
Slide 32: Our Business Model: A Model for Resolving Social Issues in Japan
Our Business Model: A Model for Resolving Social Issues in Japan, A Developed Country Facing Challenges 01 Medical Business 02 Technology Consulting Business Reforming the workstyle of Addressing the shortage medical professionals of 787,000* IT engineers Improving the profitability Mission by 2030
Slide 33: Differentiation Strategy of Designed Lab-type Development
A new value and differentiation strategy created by the「Designed Lab-type Development」 【 Risks and Concerns of Conventional Offshore Development 】 In case the of setting up an offshore base In case the of conventional Lab-type development Client Offshore development company Client’s Site Client Lab
Slide 34: Promotion of Group Businesses Based on Social Significance
Promotion of Group Businesses Based on Social Significance Considering business and capital alliances with leading global companies for the second growth phase Provision of solutions that are beneficial to three key areas: pressing need for workstyles Growing demand due to the reforms for medical do
Slide 35: ESG: For sustainable growth of business, society, and client companies
ESG：For sustainable growth of business, society, and client companies Goals Concrete Activities Related SDGs ・To make the electric power consumed at E ・To reduce CO2 emissions the head office 100% derived from renewable energy ・Global partnership ・Investment in equipment of subsidiaries in the Phili
Slide 36: Corporate Profile
Corporate Profile ■Corporate name: Ubicom Holdings, Inc. (Prime Market of TSE: 3937) ■Strategic markets: healthcare, finance, public services, automobiles, manufacturing, robotics, etc. ■Business description: Technology Consulting Business In order to solve the problem of shortage of IT engineers an
Slide 37: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements The materials and information provided in this announcement include forward-looking statements based on our current estimates and expectations at this point of time. Such forward-looking statements are subject to various risks and uncertaintie
Slide 38: Holdings, Inc.
Holdings, Inc. = fe) Q Q =) 38